Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?
After almost two years of turnover in the FDA’s top ranks, the new appointments should help ease concerns about more turmoil ahead, one analyst said.
The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda ...
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners ...
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results